January 19, 2022 4:46pm

Key word:  exposure - describes the risk and reward potential for an investor given the holdings within an investment portfolio.

The Biostage (BSTG) Chronicles: Question, WHY is the “pimp/pump and promote” in full swing with the shares appreciating +$0.25 at the sessions end with 1,516 shares traded after Tuesday’s -$0.00 with 8,288 shares trading, Friday’s -$0.32 after traveling +$0.16, +$0.19 -$0.08 -$0.10 to -$0.32 to $0.00 with 13,368 shares traded, Thursday’s +$0.02 with 700 shares traded to +$0.78 to +$0.93 to +$0.77 to +$0.28 with 31,551 shares traded <3-month average = 2,728 shares> and last Wednesday’s 44,200 shares traded? Is BSTG preparing for a reverse to register the multiple private placement non-registered shares?

Pre-open Indication results: 1 HITs, 4 MISS

If I have learned one thing as a former research analyst, venture and public markets investor then a journalist; it is that your life and your bank account are largely tied to your questioning of price movements and targets.

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?


The Dow closed DOWN -339.30 points (-0.96%); the S&P closed DOWN – 44.22 points (-0.97%) while the Nasdaq closed DOWN -166.64 points (-1.15%)

 

Henry’omics:

The cell and gene therapy sector bounced from the open but gains quickly vanished, leaving “our” universe with losses but, not as bad as yesterday’s wipe-out.

The Nasdaq fell again on Wednesday, bringing its decline from its November high to more than 10% as investors continue to dump tech shares as interest rates spike to start the new year.

After, the Nasdaq got off to a 1% higher start, but reversed having fallen nearly 10% from its prior high.

 

RegMed Investors’ (RMi) pre-open: “The oversold usually “pop” after steady declines. So, stay “pat” or consider buying a just a few past decliners” … https://www.regmedinvestors.com/articles/12262  

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Wednesday opened positive at 20 up/13 downs, 1 flat and 1 acquired, slipped negative at the mid-day at 8/24, 2 flats and 1 acquired, ending with a negative close of 9/25 and 1 acquired;

 

Pre-open indication results: 1 Hit < BioLife Solutions (BLFS -$0.14)> 4 MISS < bluebird bio (BLUE -$0.36), Editas Medicine (EDIT -$0.03), CRISPR Therapeutics (CRSP -$0.86), Biostage (OTCQB: BSTG +$0.25)>

 

The Biostage (BSTG) Chronicles: Question, WHY is the “pimp/pump and promote” in full swing with the shares appreciated +$0.25 at the sessions end with 1,516 shares traded after Tuesday’s -$0.00 with 8,288 shares trading, Friday’s -$0.32 after traveling +$0.16, +$0.19 -$0.08 -$0.10 to -$0.32 to $0.00 with 13,368 shares traded, Thursday’s +$0.02 with 700 shares traded to +$0.78 to +$0.93 to +$0.77 to +$0.28 with 31,551 shares traded <3-month average = 2,728 shares> and last Wednesday’s 44,200 shares traded?

  • Just another example of a “House of Cards” – just a game of “fake it because they can’t make it? Overhang of non-registered PPM shares is also a factor beyond the terminal and wrongful death suit which their insurance company refused to cover or reimburse which hinders indemnification of a partner and management’s personal liabilities?

 

52-week lows experiences today:

  • bluebird bio (BLUE) hit a 52-week low of $7.77
  • Fate therapeutics (FATE) hit a 52-week low of $39.91
  • Editas Medicine (EDIT) hit a 52-week low of $19.68
  • Ultragenyx Pharmaceuticals (RARE) hit a 52-week low of $66.92

 

Key Metrics:

  • Wednesday - Sector volume was LOW with 2 of 9-upside having higher than the 3-month average volume with LOW volume of 10 of 25-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday the IBB closed down -1.22% and XBI closed down -0.92%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was up +1.01 points or 4.43% at 23.80

 

Jumping with share pricing momentum (9 of 9):

  • Global Blood Therapeutics (GBT +$0.41),
  • Biostage (BSTG +$0.25 – “pumped and pimped”),
  • Ionis Pharmaceuticals (IONS +$0.20 after Tuesday’s -$2.96),
  • Sangamo Therapeutics (SGMO +$0.09),
  • Adverum Therapeutics (ADVM +$0.05),
  • Bellicum Pharmaceuticals (BLCM +$0.04),
  • Voyager Therapeutics (VYGR +$0.04),
  • Homology Medicine (FIXX +$0.01),
  • Athersys (ATHX +$0.0025 – still under a dollar, delisting?)

Hammered in today’s market (10 of 25):

  • ReNeuron (RENE.L -$3.50 after Tuesday’s -$34.00 post Monday’s holiday),
  • Intellia Therapeutics (NTLA -$2.13 after Tuesday’s -$5.57),
  • Vericel (VCEL -$1.940,
  • Fate Therapeutics (FATE -$1.31 after Tuesday’s -$2.66),
  • Ultragenyx (RARE -$0.92 after Tuesday’s -$4.38),
  • CRISPR Therapeutics (CRSP -$0.86 after Tuesday’s -$2.72),
  • Sage Therapeutics (SAGE -$0.64 after Tuesday’s -$2.85),
  • Alnylam Pharmaceuticals (ALNY -$0.57 after Tuesday’s -$9.31),
  • bluebird bio (BLUE -$0.36),
  • uniQure NV (QURE -$0.34),

Closing:

  • 1- Stemline Therapeutics (STML) – acquired

 

January, Q1/2022:

  • Wednesday closed negative with 9 incliners, 25 decliners and 1 acquired
  • Tuesday closed negative with 2 incliners, 31 decliners, 1 flat and 1 acquired
  • Monday (1/17) was a holiday

 

The BOTTOM LINE: a positive open (a + advance/decline line) moved lower in Wednesday’s “choppy waters” after Tuesday's sector’s “wipe-out”.

And I did try to “surf” the sector with some buys and sells predictions today.

January has been a rough month for the cell and gene therapy sector, so far.

Trust, conviction is lacking as Q4 and end-of-year earnings are about to be made aware of.

As I have stated, “After being oversold, when will the overbought syndrome” did NOT materialize.

Algorithms, hedge funds and traders continue to punish the cell and gene therapy stocks as valuations “creeped” up.

  • Early January 2022 can deliver some gains but also generate algorithmic based losses.

Reiterating from last year, 2021, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.